Penumbra (PEN) Net Income towards Common Stockholders Growth (1y) (2015 - 2026)
Penumbra (PEN) Net Income towards Common Stockholders Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 12.92% |
| 10 | Penumbra | 12.78 Bn | 12.12 Bn | 264.94 Mn | -23.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.16% |
| Mar 31, 2026 | -16.92% |
| Dec 31, 2025 | 40.56% |
| Sep 30, 2025 | 55.54% |
| Jun 30, 2025 | 175.27% |
| Mar 31, 2025 | 256.51% |
| Dec 31, 2024 | -37.88% |
| Sep 30, 2024 | 219.93% |
| Jun 30, 2024 | -417.91% |
| Mar 31, 2024 | 28.50% |
| Dec 31, 2023 | 1,298.45% |
| Sep 30, 2023 | 505.72% |
| Jun 30, 2023 | 613.59% |
| Mar 31, 2023 | 10,737.97% |
| Dec 31, 2022 | 115.74% |
| Sep 30, 2022 | -128.28% |
| Jun 30, 2022 | -144.43% |
| Mar 31, 2022 | -99.28% |
| Dec 31, 2021 | -1,035.90% |
| Sep 30, 2021 | 181.32% |